Orexo AB - Asset Resilience Ratio
Orexo AB (ORX) has an Asset Resilience Ratio of 0.00% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ORX strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2023)
This chart shows how Orexo AB's Asset Resilience Ratio has changed over time. See ORX net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Orexo AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Orexo AB market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Orexo AB maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Orexo AB Industry Peers by Asset Resilience Ratio
Compare Orexo AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Huadong Medicine Co Ltd
SHE:000963 |
Drug Manufacturers - Specialty & Generic | 0.05% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Orexo AB (2005–2023)
The table below shows the annual Asset Resilience Ratio data for Orexo AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | Skr0.00 ≈ $0.00 |
Skr786.60 Million ≈ $84.65 Million |
-- |
| 2022-12-31 | 19.80% | Skr219.60 Million ≈ $23.63 Million |
Skr1.11 Billion ≈ $119.35 Million |
+19.81pp |
| 2015-12-31 | 0.00% | Skr-40.00K ≈ $-4.30K |
Skr1.02 Billion ≈ $109.37 Million |
-14.78pp |
| 2006-12-31 | 14.77% | Skr56.13 Million ≈ $6.04 Million |
Skr379.93 Million ≈ $40.89 Million |
-9.37pp |
| 2005-12-31 | 24.14% | Skr89.63 Million ≈ $9.65 Million |
Skr371.31 Million ≈ $39.96 Million |
-- |
About Orexo AB
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabac… Read more